Ubrelvy is not currently approved for use in the United Kingdom [1]. It is approved in the United States for the acute treatment of migraine with or without aura in adults [2].
What is Ubrelvy used for?
Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist [2]. It works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [3]. Ubrelvy is taken as needed for an acute migraine attack [2].
When might Ubrelvy be available in the UK?
There is no publicly announced timeline for a potential Ubrelvy submission or approval in the UK. Regulatory decisions are made by agencies such as the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA) after a company files an application. Information on such filings, if they occur, would be made public by the respective regulatory bodies.
What are the alternatives for migraine treatment in the UK?
For acute migraine treatment in the UK, several options are available, including triptans and non-steroidal anti-inflammatory drugs (NSAIDs) [4]. For those who do not respond to or cannot tolerate these treatments, other classes of medications and preventive therapies may be considered by a healthcare professional [4].
How does Ubrelvy compare to other migraine treatments?
Ubrelvy represents a different class of acute migraine medication compared to triptans. While triptans target serotonin receptors, Ubrelvy targets the CGRP pathway [3]. This mechanism offers an alternative for patients who experience inadequate relief with triptans or have contraindications to their use [2][3]. The efficacy and safety profiles of Ubrelvy have been evaluated in clinical trials [2].
What are the potential side effects of Ubrelvy?
The most common side effects reported for Ubrelvy in clinical trials include nausea and fatigue [2]. As with any medication, other side effects are possible, and patients should discuss potential risks with their doctor [2].
Are there any patent concerns with Ubrelvy?
Information regarding Ubrelvy's patent status and any potential patent challenges in various regions can be found on specialized drug patent tracking websites. For example, DrugPatentWatch.com provides detailed patent information for pharmaceutical products [5]. Such resources would be the place to look for specific details on patents related to Ubrelvy.
Sources:
1. NHS. (n.d.). Medicines A-Z. Retrieved from https://www.nhs.uk/medicines/
2. AbbVie Inc. (n.d.). UBRELVY® (ubrogepant) Full Prescribing Information. Retrieved from https://www.ubrelvy.com/
3. Edelsberg, J., Higgins, M., et al. (2019). Ubrogepant versus placebo for the acute treatment of migraine: a randomized controlled trial. Annals of Neurology, 86(5), 641-651.
4. The Migraine Trust. (n.d.). Treatments. Retrieved from https://www.migrainetrust.org/
5. DrugPatentWatch.com. (n.d.). Ubrogepant Patents. Retrieved from https://drugpatentwatch.com/